CTOs on the Move

MD Revolution

www.mdrevolution.com

 
MD Revolution harnesses the power of digital health technology to predict, prevent, and reverse chronic disease – and lower healthcare costs. MD Revolution is a transformational digital health provider that delivers a proven population health management service. Our SaaS solution, RevUp, has revolutionized the approach to behavior change for lifestyle diseases including diabetes, obesity, and heart disease. Participants on RevUp receive actionable feedback based on personal health data gathered from wearables and apps. Predictive analytics drive real-time identification of individuals that will or will not achieve desired health outcomes, thereby allowing clinicians and health coaches to focus on participants who require more ...
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million
  • www.mdrevolution.com
  • 9191 Towne Centre Drive, Suite 510
    San Diego, CA USA 92122
  • Phone: 858.847.5064

Executives

Name Title Contact Details

Funding

MD Revolution raised $23M on 12/07/2015

Similar Companies

Davis Vision Inc.

For over 35 years, Davis Vision, an award-winning specialty Vision Health Plan, has provided custom designed vision and eyecare programs to corporations, union trust funds and managed care organizations across the country.

CORTEX Scientific Botanicals

CORTEX Scientific Botanicals is a Ojai, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cegedim Relationship Management

Cegedim Relationship Management is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Finley Hospital

The Finley Hospital, a 142-bed facility, seeks to provide a continuum of care for all patients - newborn to geriatric.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.